Skip to main content
    O

    OnKure Therapeutics, Inc. (OKUR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.75
    +0.12 (+4.56%)

    Market Cap: $108.33M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    OnKure Therapeutics, Inc. (OKUR) Financials: Revenue, Profit and Cash Flow

    Updated Nov 4, 2026. Financial statements from company filings, amounts in US dollars.

    OnKure Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$59.52M, operating cash flow was -$51.83M and free cash flow was -$51.87M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$17.85M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $62.95M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2020 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
    Research and development$48.26M$43.80M$32.12M$37.70M$28.17M$15.94M
    Operating income-$62.95M-$54.39M-$36.93M-$53.85M-$39.82M-$19.55M
    Net income-$59.52M-$52.67M-$35.31M-$51.95M-$39.77M-$19.46M
    EBITDA-$62.12M-$53.58M-$36.37M-$52.68M-$39.52M-$19.53M
    Fiscal years ended Dec 2020 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Gross profit$0$0$0-$202.00K$0$0$0-$419.00K$0$0$0-$291.00K
    Operating income-$19.35M-$16.90M-$15.62M-$14.13M-$15.50M-$16.32M-$17.00M-$18.70M-$11.51M-$14.34M-$9.83M$21.12M
    Net income-$17.85M-$15.35M-$15.16M-$13.50M-$14.70M-$15.39M-$15.93M-$17.44M-$11.56M-$14.14M-$9.54M$18.52M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $549.00K by $58.50M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
    Total assets$62.12M$114.91M$35.73M$108.18M$154.02M$55.22M
    Current assets$60.84M$113.00M$33.77M$106.35M$153.73M$55.02M
    Cash and equivalents$59.05M$110.76M$29.88M$19.93M$124.66M$53.61M
    Total liabilities$5.93M$11.08M$7.75M$8.21M$6.81M$4.62M
    Short-term debt$549.00K$536.00K$208.00K$151.00KN/AN/A
    Shareholder equity$56.18M$103.83M-$101.84M$99.97M$147.21M-$42.12M
    Fiscal years ended Dec 2020 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$167.08M$179.35M$198.69M$62.12M$72.83M$86.07M$99.88M$114.91M$77.64M$78.72M$84.64M$35.73M
    Total liabilities$9.34M$7.25M$14.34M$5.93M$6.41M$7.90M$9.23M$11.08M$3.63M$1.85M$3.40M$137.58M
    Cash and equivalents$151.44M$166.50M$192.11M$59.05M$70.33M$83.37M$96.66M$110.76M$60.69M$35.97M$20.38M$29.88M
    Shareholder equity$157.74M$172.11M$184.35M$56.18M$66.43M$78.17M$90.65M$103.83M$74.02M$76.87M$81.24M-$101.84M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
    Operating cash flow-$51.83M-$51.12M-$34.55M-$47.36M-$37.98M-$18.54M
    Capital expenditures$46.00K$52.00K$246.00K$346.00K$198.00K$24.00K
    Free cash flow-$51.87M-$51.17M-$34.79M-$47.71M-$38.18M-$18.56M
    Share repurchases$37.00K$4.33M$0$0N/AN/A
    Investing cash flow-$46.00K$15.87M-$246.00K-$57.84M-$23.38M$7.38M
    Financing cash flow$163.00K$116.13M$53.13M$471.00K$132.41M$47.27M
    Fiscal years ended Dec 2020 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$13.08M-$10.35M-$12.94M-$11.51M-$13.04M-$13.27M-$14.01M-$23.35M-$10.66M-$6.47M-$10.63M$9.38M
    Capital expenditures$32.00K$3.00K$5.00K$9.00K$6.00K$13.00K$18.00K$15.00K$18.00K$10.00K$9.00K$50.00K
    Free cash flow-$13.11M-$10.36M-$12.94M-$11.52M-$13.04M-$13.29M-$14.02M-$23.37M-$10.68M-$6.48M-$10.64M$9.33M
    Last 12 quarters

    Frequently Asked Questions About OKUR

    What is OnKure Therapeutics' annual revenue?

    OnKure Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is OnKure Therapeutics profitable?

    No. OnKure Therapeutics reported net income of -$59.52M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does OKUR generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$51.83M minus capital expenditures of $46.00K produced free cash flow of -$51.87M.

    How much debt does OnKure Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $549.00K and cash and equivalents of $59.05M.